PUBLISHER: The Business Research Company | PRODUCT CODE: 2106461
PUBLISHER: The Business Research Company | PRODUCT CODE: 2106461
Artificial intelligence (AI) protein design is the application of machine learning techniques and computational modeling tools to predict, engineer, and refine protein structures with specific functional characteristics. It facilitates the creation of new proteins by examining extensive biological datasets and recognizing patterns within amino acid sequences and protein folding processes. This methodology speeds up drug development, enzyme optimization, and biotechnological advancements by generating proteins that may not naturally occur.
The primary component types of artificial intelligence (AI) protein design include software, hardware, and services. Software refers to AI-powered platforms and computational tools utilized to design, refine, and predict protein structures and functions. These solutions are applied across protein types including enzymes, antibodies, therapeutic proteins, structural proteins, and signaling proteins and are delivered through on-premises and cloud deployment modes. The various applications involved include drug discovery, enzyme engineering, agricultural biotechnology, industrial biotechnology, and others, and they are utilized by multiple end users such as pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations, and others.
Tariffs are influencing the artificial intelligence (AI) protein design market by increasing the cost of imported high-performance computing hardware, GPU systems, cloud infrastructure components, and specialized bioinformatics tools required for large-scale protein modeling. This is creating higher operational expenses for research institutions and biotechnology companies, particularly in import-dependent regions such as Asia-Pacific and Europe, thereby slowing advanced drug discovery and enzyme engineering projects. Hardware-intensive segments like GPU-based protein simulation and cloud computing infrastructure are most affected due to reliance on global semiconductor supply chains. However, tariffs are also encouraging local development of computing infrastructure, expansion of regional cloud ecosystems, and increased investment in domestic biotech innovation hubs, strengthening long-term research resilience and technological independence.
The artificial intelligence (AI) protein design market size has grown exponentially in recent years. It will grow from $1.67 billion in 2025 to $2.13 billion in 2026 at a compound annual growth rate (CAGR) of 27.5%. The growth in the historic period can be attributed to progress in computational biology and bioinformatics tools, increasing availability of genomic and proteomic datasets, growing adoption of structural biology techniques such as X-ray crystallography, rising investment in pharmaceutical R&D for drug discovery, expansion of academic research in protein folding and molecular biology.
The artificial intelligence (AI) protein design market size is expected to see exponential growth in the next few years. It will grow to $5.68 billion in 2030 at a compound annual growth rate (CAGR) of 27.7%. The growth in the forecast period can be attributed to the rising adoption of AI-driven drug discovery platforms, increasing integration of cloud computing in life sciences research, growing demand for personalized and precision medicine solutions, expansion of synthetic biology and engineered protein applications, and increasing use of quantum computing for molecular simulation and protein design. Major trends in the forecast period include AI-driven de novo protein structure prediction and optimization platforms, machine learning-based enzyme engineering for industrial and therapeutic applications, cloud-based protein modeling and bioinformatics simulation platforms, generative AI for custom therapeutic protein and antibody design, and high-throughput computational protein screening and virtual testing systems.
The increasing focus on biologics is expected to propel the growth of the artificial intelligence (ai) protein design market going forward. Biologics are therapeutic products derived from living organisms or their components that target specific pathways in the immune system to treat diseases. The emphasis on biologics is growing due to advancements in biotechnology and immunology, which have enabled the development of more precise and effective treatments that target the underlying mechanisms of immune-mediated conditions rather than merely managing symptoms. Artificial intelligence (ai) protein design accelerates biologics development by enabling the rapid discovery and optimization of protein structures with improved therapeutic efficacy, stability, and target specificity. For instance, in February 2025, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, the 2023 WHO Essential Medicines List includes 81 biologic therapies, representing over 15% of all listed medicines. Therefore, the increasing focus on biologics is driving the growth of artificial intelligence (ai) protein design market.
Key companies operating in the artificial intelligence (AI) protein design market are focusing on developing innovative solutions, such as advanced deep learning-based molecular modeling systems to accelerate accurate protein structure prediction, enhance drug discovery efficiency, and enable the design of novel therapeutics with improved precision. Advanced deep-learning based molecular modeling systems are AI-driven computational tools that use neural networks to simulate and predict the structures, behaviors, and interactions of molecules, such as proteins and drugs, with high accuracy to support scientific research and drug development. For example, in May 2024, DeepMind Technologies Limited, a UK-based artificial intelligence research company, launched its latest protein structure prediction model, AlphaFold 3, which significantly advances the ability to model complex biomolecular interactions, including proteins, DNA, RNA, and small molecules. The system builds on previous versions by improving prediction accuracy and enabling a more comprehensive understanding of how biological molecules interact in real cellular environments. AlphaFold 3 leverages deep neural networks trained on large-scale biological datasets to generate highly accurate 3D protein structures, reducing reliance on time-consuming experimental methods such as X-ray crystallography and cryo-electron microscopy and thereby accelerating innovation in drug discovery and life sciences research.
In January 2026, Insitro Inc., a US-based techbio organization, acquired CombinAbleAI for an undisclosed amount. With this acquisition, Insitro seeks to enhance and complete its comprehensive, modality-agnostic AI platform for drug discovery and design by incorporating advanced protein and molecular design capabilities. CombinAble.AI Ltd. is an Israel-based firm offering AI-driven software solutions for protein and molecular design.
Major companies operating in the artificial intelligence (AI) protein design market are Nvidia Corporation, DeepMind Technologies Limited, Schrodinger Inc., XtalPi Inc., Absci Corporation, Isomorphic Labs, Insilico Medicine Inc., Generate Biomedicines Inc., BenevolentAI Limited, EvolutionaryScale PBC, RosettaVIOLabs (Institute for Protein Design), Terray Therapeutics, Arzeda Corporation, Basecamp Research Ltd., Evozyne Inc., Profluent Bio Inc., Aqemia SAS, A-Alpha Bio Inc., Cradle Bio BV, Archon Biosciences Inc., Monod Bio Inc., Tamarind Bio Inc., Levitate Bio Inc., Denov Artificial Intelligence Biotech, Menten Artificial Intelligence Inc.
North America was the dominant region in the artificial Intelligence (AI) protein design market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in artificial intelligence (AI) protein design report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the artificial intelligence (AI) protein design market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The artificial intelligence (AI) protein design market consists of revenues earned by entities by providing services such as de novo protein design, antibody discovery, protein structure prediction, molecular dynamics simulation services, and protein-ligand interaction modeling. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) protein design market also includes sales of rack-scale compute systems, edge AI compute device, molecular simulation workstations, and automated protein synthesis systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The artificial intelligence (AI) protein design market research report is one of a series of new reports from The Business Research Company that provides artificial intelligence (AI) protein design market statistics, including artificial intelligence (AI) protein design industry global market size, regional shares, competitors with a artificial intelligence (AI) protein design market share, detailed artificial intelligence (AI) protein design market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) protein design industry. This artificial intelligence (AI) protein design market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Artificial Intelligence (AI) Protein Design Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses artificial intelligence (ai) protein design market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for artificial intelligence (ai) protein design ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The artificial intelligence (ai) protein design market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.